Adocia Adds $200M To Arbitration Demand Against Eli Lilly

Law360 (February 6, 2018, 7:07 PM EST) -- French biopharmaceutical company Adocia SA is seeking over $200 million more in damages from Eli Lilly and Co. in arbitration over an abandoned partnership on the diabetes treatment BioChaperone Lispro, adding claims that Lilly misused Adocia's trade secrets and breached confidentiality agreements.

Adocia, which focuses on treating diabetes and other metabolic diseases, said Tuesday that it bolstered ongoing arbitration against Indiana-based Lilly with claims about its “misappropriation and improper use of Adocia’s confidential information and discoveries” and “breaches of several collaboration and confidentiality agreements.”

“Adocia anticipates...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.